Prothena CORP Public LTD CO

Prothena Corporation shareholders re-elected directors, ratified the appointment of KPMG LLP, and approved executive compensation at the 2026 Annual General Meeting.

Prothena Corporation plc announced a share repurchase plan of up to $100 million, expiring December 31, 2026, leveraging its strong cash position.

Prothena reported its fourth quarter and full year 2025 financial results, highlighting significant advancements in its partnered clinical programs and providing 2026 financial guidance.

Prothena Corporation plc announced the resignation of Board Director Paula Cobb, effective December 31, 2025.

Prothena Corporation plc shareholders approved a capital reduction to create distributable reserves, enhancing financial flexibility.

Prothena reports Q3 2025 financial results, highlighting significant advancements in its late-stage clinical pipeline and plans for a potential share redemption program.

Prothena Corporation plc reported a significant net loss of $222.5 million for the nine months ended September 30, 2025, driven by R&D wind-downs and a corporate restructuring, while advancing key partnered neurodegenerative programs.

Prothena Corporation plc reported a significant net loss in Q2 2025, driven by the discontinuation of its birtamimab program and a substantial workforce reduction, while advancing its key neuroscience pipeline.

Prothena Corporation plc reports its financial results for the quarter ended March 31, 2025, and provides updates on its clinical development programs.

Prothena Corporation's Q3 2024 report details a significant shift in revenue streams and ongoing clinical trial progress, alongside strategic collaborations.

Prothena Corporation reports a significant increase in revenue for the second quarter of 2024, primarily due to a licensing agreement with Bristol Myers Squibb, while also progressing its clinical programs.

Prothena Corporation's first quarter 2024 results show a net loss of $72.2 million, with increased R&D spending and no collaboration revenue, while the company continues to advance its clinical programs.

Prothena's 2025 annual report highlights advancements in its partnered neurodegenerative and amyloidosis programs, alongside a significant workforce reduction and a net loss of $244.1 million.

Prothena Corporation's 2024 10-K filing highlights the company's focus on developing therapies for neurodegenerative and rare peripheral amyloid diseases, with key clinical trial milestones expected in 2025.

Prothena Corporation plc details its share capital, shareholder rights, and corporate governance practices in its latest 10-K filing.

Wagner M. Zago, Chief Scientific Officer of Prothena Corp Public Ltd Co, reported multiple transactions in common stock on July 28, 2026.

Karin L Walker, Chief Accounting Officer of Prothena Corp Public Ltd Co, reported multiple transactions in common stock on July 28, 2026.

Chad J. Swanson, Chief Development Officer of Prothena Corp Public Ltd Co, reported multiple transactions in common stock on July 28, 2026.

Brandon S. Smith, Chief Operating Officer of Prothena Corp Public Ltd Co, reported multiple transactions in common stock on July 28, 2026.

Tran Nguyen, Chief Strategy Officer and CFO of Prothena Corp Public Ltd Co, reported multiple transactions in common stock on July 28, 2026.

Gene G. Kinney, President and CEO and a Director of Prothena Corp Public Ltd Co, reported multiple transactions in common stock on July 28, 2026.

Prothena Corporation plc announces its 2026 Annual General Meeting to address director elections, auditor ratification, and executive compensation.

Prothena Corporation plc announced third quarter 2025 financial results and significant advancements in its late-stage clinical programs for neurodegenerative and rare diseases.

Prothena Corporation Public Limited Company has filed definitive additional proxy materials with the SEC.

Prothena Corporation plc is convening an Extraordinary General Meeting to approve a capital reduction, aiming to create distributable reserves for potential future shareholder distributions, including a share redemption program.

Prothena Corporation has filed a definitive proxy statement with the SEC, related to its upcoming shareholder meeting.

Prothena Corporation is holding its Annual General Meeting on May 13, 2025, seeking shareholder approval for director elections, auditor ratification, executive compensation, and an amendment to the 2018 Long Term Incentive Plan.

Investment firm EcoR1 Capital, LLC and its affiliates have sold their entire holdings in Prothena Corp Public Ltd Co, no longer beneficially owning more than five percent of the company's Ordinary Shares as of May 28, 2025.

Investment firm EcoR1 Capital and its affiliates have significantly reduced their beneficial ownership in Prothena Corp Public Ltd Co, selling over 6.2 million ordinary shares in early May 2025.

EcoR1 Capital, LLC and its affiliates report a continued 21.5% beneficial ownership in Prothena Corporation plc, while Oleg Nodelman, a key figure, has resigned from Prothena's board of directors.

Rubric Capital Management LP and David Rosen have reported a 9.29% beneficial ownership stake in Prothena Corporation plc.

William P. Scully has disclosed beneficial ownership of 5,378,846 ordinary shares, representing approximately 10.3% of Prothena Corp Public Ltd Co.

Rubric Capital Management LP and David Rosen have disclosed a passive 6.83% beneficial ownership stake in Prothena Corporation Public Limited Company as of December 31, 2025.

ADAR1 Capital Management, along with its affiliates and manager Daniel Schneeberger, reported a beneficial ownership of 2.7% in Prothena Corporation Public Limited Company as of September 30, 2025.

Todd W. Fennell has reported a beneficial ownership of 8.35% of Prothena Corp Public Ltd Co's Ordinary Shares, held primarily through various trusts.

William P. Scully has filed an amended Schedule 13G, disclosing a beneficial ownership of 9.8% of Prothena Corp Public Ltd Co's Ordinary Shares.